Clinical Trials Directory

Trials / Recruiting

RecruitingNCT06968312

Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD

Testing Potential Enhancement of Standard Cognitive Processing Therapy for PTSD Using Hexadecanal: A Randomized Controlled Trial

Status
Recruiting
Phase
N/A
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Tel Aviv University · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.

Detailed description

In this triple blind (patient, therapist, independent evaluator) RCT, 40 patients with PTSD receiving standard Cognitive Processing Therapy will be randomized in a 1:1 ratio to receive either odorless Hexadecanal molecules or odorless mineral oil molecules (Control) diffused in the treatment room at all therapy sessions. Inclusion criteria: age\>18 years, PTSD diagnosis according to DSM-5-TR. Exclusion: Bipolar, psychotic, or neurological disorders, drug abuse, any parallel psychotherapy, anosmia. Primary outcome: pre-to-post treatment change in PTSD symptom severity measured by the PTSD check List for DSM-5 (PCL-5). Additional outcomes: Depression (PHQ-9), anxiety (GAD-7), Anger (DAR-5), therapeutic alliance (WAI-SF).

Conditions

Interventions

TypeNameDescription
OTHERCognitive Processing Therapy + HexadecanalCognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD.
OTHERHexadecanal - Molecule Distribution in the Therapy roomDistribution of a naturally secreted molecule from body odor (Hexadecanal).

Timeline

Start date
2025-05-05
Primary completion
2026-09-30
Completion
2026-12-30
First posted
2025-05-13
Last updated
2025-05-16

Locations

1 site across 1 country: Israel

Source: ClinicalTrials.gov record NCT06968312. Inclusion in this directory is not an endorsement.